title: Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
abstract: OBJECTIVE
  To study the potential pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline at steady state.
  
  
  METHODS
  Theophylline 200 mg extended-release formulation was administered twice daily on days 1-11 to 30 healthy, non-smoking males. On days 5-11, 15 subjects received concomitant lansoprazole 30 mg once daily (o.d.) and 15 subjects received concomitant pantoprazole 40 mg o.d.
  
  
  RESULTS
  No significant changes in the steady-state theophylline maximum plasma concentration (Cmax), time to Cmax (Tmax), minimum plasma concentration (Cmin), area under the plasma concentration-time curve over the 12-h dosing interval (AUC0-12), or apparent total oral clearance (CL/F) were observed within the two treatment groups when theophylline was administered alone or in combination with lansoprazole or pantoprazole. In addition, no significant differences in the changes of steady-state theophylline pharmacokinetics from day 4 to day 11 were noted between the two treatment groups. Treatment with theophylline in combination with either lansoprazole or pantoprazole was well tolerated. All adverse events were transient and rated mild to moderate in severity.
  
  
  CONCLUSIONS
  Co-administration of either lansoprazole or pantoprazole in healthy subjects does not significantly affect the steady-state pharmacokinetics of theophylline at the therapeutic doses tested.
authors.affiliation: Abbott Laboratories, Abbott Park, Illinois 60064-6104, USA.
authors.forename: W J
authors.initials: WJ
authors.lastname: Pan
authors.forename: D R
authors.initials: DR
authors.lastname: Goldwater
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.forename: B L
authors.initials: BL
authors.lastname: Pilmer
authors.forename: R H
authors.initials: RH
authors.lastname: Hunt
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001562:Benzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics*; D001682:Biological Availability; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations; D004347:Drug Interactions; D006801:Humans; D064747:Lansoprazole; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D016037:Single-Blind Method; D013454:Sulfoxides / Q000009:adverse effects / Q000493:pharmacokinetics*; D013806:Theophylline / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D064747:Lansoprazole; D013806:Theophylline; D000077402:Pantoprazole; D009853:Omeprazole